Please login to the form below

Not currently logged in
Email:
Password:

Gedeon Richter strengthens its biotechnology business

Gedeon Richter, and Helm, its German partner, have purchased Strathmann Biotec for EUR 22.9m to expand both companies' biotechnology research activities

Hungary-based generics manufacturer, Gedeon Richter, and Helm, its German partner, have purchased German-headquartered Strathmann Biotec for EUR 22.9m to expand both companies biotechnology research activities.

The joint venture will be 70 per cent owned by Gedeon Richter, with Helm holding the remaining 30 per cent. The deal is subjected to regulatory approval.

Strathmann Biotec has a biotechnology plant for bacterial biotechnology, as well as an R&D laboratory and pilot plant capacity. The company employs 81 staff.

Gedeon Richter says that its strategic goal is to establish a strong biopharmaceutical line to expand its worldwide product portfolio by offering products with high added value.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics